Скачать или смотреть IAEA Recommends Global Adoption of PSMA-PET for Prostate Cancer Staging: What You Need to Know

A groundbreaking study published in the Journal of Nuclear Medicine supports the global adoption of Gallium-68 (Ga-68) PSMA-11 PET/CT for staging high-risk prostate cancer. This video breaks down the key findings of the IAEA-sponsored trial, which involved 775 men across 11 countries with varying income levels. Learn how PSMA-PET/CT outperformed MRI in detecting metastatic disease, altering treatment plans, and preventing unnecessary surgeries. We’ll also discuss the implications for patients worldwide, including challenges like cost and accessibility, especially in low- and middle-income countries. Whether you're a healthcare professional, a patient, or simply interested in medical advancements, this video provides essential insights into the future of prostate cancer staging.
Key Topics Covered:
What is PSMA-PET/CT and how does it work?
Study findings: PSMA-PET/CT vs. MRI for prostate cancer staging
Impact on treatment decisions and patient outcomes
Global accessibility and cost considerations
Future research and follow-up studies
Keywords: PSMA-PET, Prostate Cancer, IAEA, Ga-68 PSMA-11, PET/CT, MRI, Cancer Staging, Nuclear Medicine, High-Risk Prostate Cancer, Global Healthcare